Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide and Leuprolide Acetate in AR+ Salivary Gland Cancer
NCT05669664Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in salivary gland cancer (SGC), sponsored by National Cancer Institute. Started Jul 2023; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT05669664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669664.